Nonoccupational postexposure prophylaxis regimens: preferred and alternate agents*
| Drug category† | Preferred | Alternate |
|---|---|---|
| Two nucleoside reverse transcriptase inhibitors | TDF/FTC 300/200 mg PO once daily (strong recommendation; low quality of evidence) | Zidovudine/lamivudine 300/150 mg PO twice daily (weak recommendation; low quality of evidence) or TDF 300 mg PO once daily + lamivudine 300 mg PO once daily (weak recommendation; low quality of evidence) |
| Third drug | Darunavir 800 mg PO once daily + ritonavir 100 mg PO once daily (strong recommendation; high quality of evidence) or Dolutegravir 50 mg PO once daily (strong recommendation; low quality of evidence) or Raltegravir 400 mg PO twice daily (strongrecommendation; high quality of evidence) | Atazanavir 300 mg PO once daily + ritonavir 100 mg PO once daily (weak recommendation; low quality of evidence) or Darunavir/cobicistat 800/150 mg PO once daily (weak recommendation; very low quality of evidence) or Elvitegravir/cobicistat 150/150 mg (coformulated with TDF/FTC 300/200 mg) PO once daily (weak recommendation; low quality of evidence) or Lopinavir/ritonavir 800/200 mg PO once daily (weak recommendation; strong quality of evidence) or Raltegravir HD 1200 mg PO once daily (weak recommendation; very low quality of evidence) |
| NOT recommended | ||
| Abacavir, didanosine, efavirenz, nevirapine, stavudine | ||
Note: nPEP = nonoccupational postexposure prophylaxis, PO = per os (orally), FTC = emtricitabine, TDF = tenofovir disoproxil fumarate.
↵* A thorough medication history (including prescription drugs, supplements, herbal preparations) should be taken before selecting an nPEP regimen because of the potential for drug–drug interactions.
↵† A complete nPEP regimen includes two nucleoside reverse transcriptase inhibitors plus a third drug.